With these evidences, AZD9291 (osimertinib), HM61713 (olmutinib), CO-1686 (rociletinib) and others (ASP8273, EGF816) are object of several clinical trials and AZD9291 has already obtained FDA and EMA approval for the therapy of EGFR mutant T790M-positive NSCLC [46]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.